特发性肺纤维化抗凝治疗的研究进展  

Update research of anticoagulant therapy in idiopathic pulmonary fibrosis

作　　者：熊丽[1] 胡良安[2] 

机构地区：[1]四川省医学科学院四川省人民医院城东病区呼吸内科,成都610101 [2]重庆医科大学附属第一医院呼吸内科,400016

出　　处：《国际呼吸杂志》2016年第1期74-78,共5页International Journal of Respiration

摘　　要：特发性肺纤维化（idiopathic pulmonary fibrosis，IPF）是一种病因不明的慢性进展性纤维化型间质性肺炎，组织病理学和／或影像学表现具有寻常型间质性肺炎的特征。随着对IPF发病机制研究的不断深入，许多新的治疗方法及药物逐步受到重视。凝血级联在肺纤维化发病过程中发挥重要作用，为IPF抗凝治疗提供了理论依据。传统抗凝药物低分子肝素、华法林等在IPF抗凝疗效的研究结论不相一致，新型抗凝药物达比加群酯在肺纤维化中的研究为其治疗间质性肺疾病的可行性和有效性研究提供了临床前信息。本文就IPF抗凝治疗研究进展进行综述。Idiopathic pulmonary fibrosis （IPF） is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia with unknown cause, and associated with the histopathologic and/or radiologie pattern of usual interstitial pneumonia. With the further researches on the pathogenesis of IPF, many new treatments and medicines are paid attention to. Coagulation cascade plays an important role in the pathogenesis of pulmonary fibrosis, providing theoretical basis for anticoagulant therapy in IPF. There are different conclusions on the studies of traditional anticoagulant drugs such as low molecular weight heparin and warfarin for IPF treatment. The researches on novel anticoagulant drug dabigatran etexilate for pulmonary fibrosis provide preclinical information about the feasibility and efficacy of dabigatran etexilate as a new therapeutic approach for the treatment of interstitial lung disease. This article reviews the update research of anticoagulant therapy in IPF.

关 键 词：特发性肺纤维化 治疗 低分子肝素 华法林 达比加群酯 血栓调节蛋白 

分 类 号：R563.9[医药卫生—呼吸系统]